HC Wainwright Reaffirms “Buy” Rating for Bio-Path Holdings, Inc. (BPTH)

HC Wainwright reiterated their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a research note published on Monday, Marketbeat Ratings reports. HC Wainwright currently has a $1.50 price target on the stock, down from their previous price target of $4.50.

Separately, ValuEngine lowered Bio-Path Holdings from a sell rating to a strong sell rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $1.67.

Shares of Bio-Path Holdings (NASDAQ BPTH) traded down $0.01 during mid-day trading on Monday, reaching $0.29. The company’s stock had a trading volume of 236,400 shares, compared to its average volume of 394,712. Bio-Path Holdings has a 12 month low of $0.25 and a 12 month high of $1.38.

Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). equities research analysts forecast that Bio-Path Holdings will post -0.08 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Reaffirms “Buy” Rating for Bio-Path Holdings, Inc. (BPTH)” was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://baseballnewssource.com/markets/hc-wainwright-reaffirms-buy-rating-for-bio-path-holdings-inc-bpth/1781450.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPTH. Legal & General Group Plc grew its position in Bio-Path Holdings by 5,474.3% in the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after acquiring an additional 1,741,978 shares in the last quarter. Sabby Management LLC grew its position in Bio-Path Holdings by 73.2% in the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock valued at $462,000 after acquiring an additional 503,488 shares in the last quarter. Bank of New York Mellon Corp grew its position in Bio-Path Holdings by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after acquiring an additional 5,172 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in Bio-Path Holdings by 0.3% in the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after acquiring an additional 4,000 shares in the last quarter. 15.15% of the stock is owned by institutional investors.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity
Red Sox Want Sluggers, Giancarlo Stanton May Become Available
Red Sox Want Sluggers, Giancarlo Stanton May Become Available
Rangers Able to Pay More for Shohei Otani Than Others
Rangers Able to Pay More for Shohei Otani Than Others


Leave a Reply

 
© 2006-2017 BBNS.